IncRNA MAFG-AS1 Contributes to Esophageal Squamous-Cell Carcinoma Progression via Regulating miR143/LASPI [Retraction]

Qu Y, Liu J. *Onco Targets Ther.* 2020;13:8359–8370.

The Editor and Publisher of *OncoTargets and Therapy* wish to retract the published article.

The journal was notified of potential image duplication in:

- Figure 3A – panel EC109 si-MAFG-AS1#2 and Figure 3C – panel EC109 si-NC, which appear to be duplicates of each other.
- Figure 3C – panel EC1 si-MAFG-AS1#2 and Figure 3G – panel EC1 GV-NC, which appear to be duplicates of each other.

The authors did not provide the necessary raw data for their study and the editor determined the findings of the study were no longer valid and requested for the paper to be retracted.

Our decision-making was informed by our policy on publishing ethics and integrity and the COPE guidelines on retraction.

The retracted article will remain online to maintain the scholarly record, but it will be digitally watermarked on each page as “Retracted”.

Publish your work in this journal

OncoTargets and Therapy is an international, peer-reviewed, open access journal focusing on the pathological basis of all cancers, potential targets for therapy and treatment protocols employed to improve the management of cancer patients. The journal also focuses on the impact of management programs and new therapeutic

agents and protocols on patient perspectives such as quality of life, adherence and satisfaction. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.

Submit your manuscript here: <https://www.dovepress.com/oncotargets-and-therapy-journal>